Ocular absorption, blood levels, and excretion of dorzolamide, a topically active carbonic anhydrase inhibitor

Journal of Ocular Pharmacology and Therapeutics

Volumn 13, Issue 1, 1997, Pages 23-30

  Maren, Thomas H ^a   Conroy, Curtis W ^a   Wynns, George C ^b   Levy, Norman S ^b  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b Florida Ophthalmic Institute   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETAZOLAMIDE; CARBONATE DEHYDRATASE; CARBONATE DEHYDRATASE INHIBITOR; DORZOLAMIDE; DRUG METABOLITE; METHAZOLAMIDE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG ABSORPTION; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG ERYTHROCYTE LEVEL; DRUG EXCRETION; DRUG METABOLISM; DRUG URINE LEVEL; FEMALE; HUMAN; HUMAN CELL; INTRAOCULAR HYPERTENSION; KIDNEY CLEARANCE; MALE; OPEN ANGLE GLAUCOMA; TOPICAL DRUG ADMINISTRATION;

EID: 0030891498     PISSN: 10807683     EISSN: None     Source Type: Journal    
DOI: 10.1089/jop.1997.13.23     Document Type: Article

References (11)

1. Maren, T.H. The development of topical carbonic anhydrase inhibitors. J. Glaucoma, 4:49-62, 1995.
2. Sugrue, M.F. The preclinical pharmacology of dorzolamide hydrochloride, a topical carbonic anhydrase inhibitor. J. Ocul. Pharmacol.Ther., 12:363-376, 1996.
3. Wilkerson, M., Cyrlin, M., Lippa, E.A., Esposito, D., Deasy, D., Panebianco, D., Fazio, R., Yablonski, M. and Shields, M.B. Four-week safety and efficacy study of dorzolamide, a novel, active topical carbonic anhydrase inhibitor. Arch. Ophthalmol., 111:1343-1350, 1993.
4. Biollaz, J., Munafo, A., Buclin, T., Gervasoni, J.-P., Magnin, J.-L., Jaquet, F. and Brunner-Ferber, F. Whole-blood pharmacokinetics and metabolic effects of the topical carbonic anhydrase inhibitor dorzolamide. Eur. J. Clin. Pharmacol., 47:453-460, 1995.
5. Maren, T.H., Bar-Ilan, A., Conroy, C.W. and Brechue, W.F. Chemical and pharmacological properties of MK-927, a sulfonamide carbonic anhydrase inhibitor that lowers intraocular pressure by the topical route. Exp. Eye Res., 50:27-36, 1990.
6. Maren, T.H., Rayburn, C.S. and Liddell, N.E. Inhibition by anions of human red cell carbonic anhydrase B: Physiological and biochemical implications. Science, 191:469-472, 1976.
7. Conroy, C.W. and Maren, T.H. The effect of temperature on the binding of sulfonamides to carbonic anhydrase isoenzymes I, II, and IV. Molec. Pharmacol., 48:486-491, 1995.
8. Maren, T.H., Robinson, B., Palmer, R.F. and Griffith, M.E. The binding of aromatic sulfonamides to erythrocytes. Biochem. Pharmacol., 6:21-46, 1961.
9. Maren, T.H. Carbonic anhydrase: Chemistry, physiology, and inhibition. Physiol. Rev., 47:595-781, 1967.
10. Maren, T.H. The binding of inhibitors to carbonic anhydrase in vivo: Drugs as markers for enzyme. Biochem. Pharmacol., 9:39-48, 1962.
11. Maren, T.H. Relations between structure and biological activity of sulfonamides. Ann. Rev. Pharmacol. Toxicol., 16:309-327, 1976.